



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Rossella MUSA et al

SERIAL NO: 10/628,453

FILED: July 29, 2003

FOR: MODIFIED CARRIER PARTICLES FOR USE IN DRY POWDER INHALERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicants wish to disclose the following information.

**REFERENCES**

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Roland E. Martin  
Registration No. 48,082

DEC 30 2003

SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 241019US0DIV	SERIAL NO. 10/628,453		
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Rossella MUSA et al					
		FILING DATE July 29, 2003		GROUP			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
AM							
AN							
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
				WIPO	YES	NO	XXX
AO	WO 00/28979	05/25/00		WIPO			XXX
AP							
AQ							
AR							
AS							
AT							
AU							
AV							
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AW						
	AX						
	AY						
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

DOCKET NO.: 241019US0DIV



Re: In re Application of: Rossella MUSA et al  
U.S. Application Serial No.: 10/628,453  
Filing Date: July 29, 2003  
For: MODIFIED CARRIER PARTICLES FOR USE IN DRY  
POWDER INHALERS

STATEMENT OF RELEVANCY

References WO 96 23485; DE 44 25 255, WO 95/11666 and GB 2 107 715 cited in the attached European Search Report were previously submitted to the U.S. Patent and Trademark Office in an Information Disclosure Statement (IDS) filed on July 29, 2003. Therefore, copies of these cited references are not included in the attached Information Disclosure Statement (IDS) filed herewith.